Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Ask Theory

042: [Health & Environment Research] "Forever Chemicals" sa Katawan: Paano Ba Maiiwasan? (with Dr. Michael Velarde)

02 Oct 2021

Description

This episode features Dr. Michael C. Velarde, a professor at the Institute of Biology, University of the Philippines Diliman. He has a strong background in the study of female reproduction, aging, and related diseases. One of his research projects involves studying how environmental chemicals influence disease development and progression. We talked about PFAS and the health risks associated with them, the gaps in Philippine research regarding women’s health, how Filipinos are affected by PFAS, the dangers of immediately drawing conclusions from limited scientific data, involving young Pinoy students and scientists in health and environment research, and more. [0:00] A quotable quote from Dr. Michael Velarde. [1:13] Introducing Dr. Michael. [2:49] More information about Dr. Michael. [6:48] Dr. Michael’s mission as a scientist. [11:19] The state of research on women’s health in the Philippines. [13:58] Understanding PFAS: What they are, and the dangers associated with them. [16:12] Why PFAS stay in the body after consumption. [17:41] How Filipinos are affected by PFAS. [20:49] Why we should be cautious when interpreting new scientific data. [25:07] How to limit PFAS exposure - and if it’s possible to expel PFAS from the body. [32:08] How Dr. Michael involves students and young scientists in research related to the environment and health. [35:50] The best way to reach out to Dr. Michael. [36:28] Dr. Michael’s advice to aspiring Filipino scientists. How to contact Dr. Michael Velarde: Email: [email protected]

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.